Literature DB >> 23013078

Enzalutamide--a major advance in the treatment of metastatic prostate cancer.

Nicholas J Vogelzang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23013078     DOI： 10.1056/NEJMe1209041

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.

Authors:  Dominic Pilon; Ajay S Behl; Lorie A Ellis; Marie-Noëlle Robitaille; Patrick Lefebvre; Nancy A Dawson
Journal:  Am Health Drug Benefits       Date:  2017-05

Review 2.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

3.  Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.

Authors:  Ronghao Wang; Yin Sun; Lei Li; Yuanjie Niu; Wanying Lin; Changyi Lin; Emmanuel S Antonarakis; Jun Luo; Shuyuan Yeh; Chawnshang Chang
Journal:  Eur Urol       Date:  2017-05-18       Impact factor: 20.096

Review 4.  Enzalutamide for patients with metastatic castration-resistant prostate cancer.

Authors:  Wijdan H Ramadan; Wissam K Kabbara; Hiba S Al Basiouni Al Masri
Journal:  Onco Targets Ther       Date:  2015-04-17       Impact factor: 4.147

5.  Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer.

Authors:  Min Guan; Leila Su; Yate-Ching Yuan; Haiqing Li; Warren A Chow
Journal:  Sci Rep       Date:  2015-04-16       Impact factor: 4.379

6.  TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.

Authors:  Chao Liang; Shangqian Wang; Chao Qin; Meilin Bao; Gong Cheng; Bianjiang Liu; Pengfei Shao; Qiang Lv; Ninghong Song; Lixin Hua; Min Gu; Jie Li; Zengjun Wang
Journal:  Cell Death Dis       Date:  2018-02-05       Impact factor: 9.685

Review 7.  Enzalutamide: a new agent for the prostate cancer treatment armamentarium.

Authors:  Stephanie B McCutcheon
Journal:  J Adv Pract Oncol       Date:  2013-05

8.  Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Authors:  Nada Lallous; Stanislav V Volik; Shannon Awrey; Eric Leblanc; Ronnie Tse; Josef Murillo; Kriti Singh; Arun A Azad; Alexander W Wyatt; Stephane LeBihan; Kim N Chi; Martin E Gleave; Paul S Rennie; Colin C Collins; Artem Cherkasov
Journal:  Genome Biol       Date:  2016-01-26       Impact factor: 13.583

9.  The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.

Authors:  Bianjiang Liu; Yin Sun; Min Tang; Chao Liang; Chi-Ping Huang; Yuanjie Niu; Zengjun Wang; Chawnshang Chang
Journal:  Cell Death Dis       Date:  2020-09-25       Impact factor: 8.469
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.